Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H21ClN6O3 |
| Molecular Weight | 464.904 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)\C=C2/N=C3CN=C(C4=CC=CC=C4Cl)C5=CC(=CC=C5N3C2=O)[N+]([O-])=O
InChI
InChIKey=UTEFBSAVJNEPTR-RGEXLXHISA-N
InChI=1S/C23H21ClN6O3/c1-27-8-10-28(11-9-27)14-19-23(31)29-20-7-6-15(30(32)33)12-17(20)22(25-13-21(29)26-19)16-4-2-3-5-18(16)24/h2-7,12,14H,8-11,13H2,1H3/b19-14-
| Molecular Formula | C23H21ClN6O3 |
| Molecular Weight | 464.904 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
DescriptionSources: www.mhra.gov.uk/home/groups/par/documents/websiteresources/con418469.pdfCurator's Comment: description was created based on several sources, including, http://home.intekom.com/pharm/hmr/dormnoct.html
Sources: www.mhra.gov.uk/home/groups/par/documents/websiteresources/con418469.pdf
Curator's Comment: description was created based on several sources, including, http://home.intekom.com/pharm/hmr/dormnoct.html
Loprazolam is a hypnotic drug which stimulates GABA-A receptors. Due to its hypnotic activity the drug is used to treat short-term sleep disordes.
CNS Activity
Sources: http://home.intekom.com/pharm/hmr/dormnoct.html
Curator's Comment: The drug is hypnotic.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2109243 Sources: www.mhra.gov.uk/home/groups/par/documents/websiteresources/con418469.pdf |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | DORMONOCT Approved UseShort-term treatment of insomnia.Sleep disturbances in the geriatric patient. Pre-operative sleep disturbances. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2864049/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
LOPRAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2864049/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
LOPRAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860916/ |
1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LOPRAZOLAM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
4.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860916/ |
1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LOPRAZOLAM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
46.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2864049/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
LOPRAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
74.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2864049/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
LOPRAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
35.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860916/ |
1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LOPRAZOLAM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
50 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860916/ |
1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LOPRAZOLAM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
11.22 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2864049/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
LOPRAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
19.77 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2864049/ |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
LOPRAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860916/ |
1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LOPRAZOLAM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
3.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860916/ |
1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LOPRAZOLAM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
15% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6140793/ |
LOPRAZOLAM plasma | Homo sapiens |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1 mg 7 times / day multiple, oral Recommended Dose: 1 mg, 7 times / day Route: oral Route: multiple Dose: 1 mg, 7 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
2 mg single, oral Recommended |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Lethargy, Dizziness... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Lethargy | 2 mg single, oral Recommended |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
| Ataxia | 20% | 2 mg single, oral Recommended |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Dizziness | 20% | 2 mg single, oral Recommended |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: http://home.intekom.com/pharm/hmr/dormnoct.html
The usual adult dose is 1 - 2 mg at bedtime.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:07:56 GMT 2025
by
admin
on
Mon Mar 31 18:07:56 GMT 2025
|
| Record UNII |
759N8462G8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DEA NO. |
2773
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
||
|
WHO-VATC |
QN05CD11
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
||
|
NCI_THESAURUS |
C1012
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
||
|
WHO-ATC |
N05CD11
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
759N8462G8
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
DTXSID30894873
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
C66032
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
3033860
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
4884
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
m6901
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | Merck Index | ||
|
1602
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
38555
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | RxNorm | ||
|
61197-73-7
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
SUB08576MIG
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
100000082009
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
LOPRAZOLAM
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
DB13643
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
C020168
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
CHEMBL2107448
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |